Literature DB >> 21924997

Mycophenolate mofetil for the management of autoimmune bullous diseases.

Marina Eskin-Schwartz1, Michael David, Daniel Mimouni.   

Abstract

Immunosuppressive agents such as azathioprine, cyclophosphamide, and mycophenolate mofetil (MMF) are now widely used in the treatment of autoimmune bullous diseases. This article reviews the use of MMF for the treatment of several bullous conditions, and assesses the evidence gathered from clinical trials and case series. According to numerous case series, MMF could be of value in treating refractory disease. The few randomized clinical trials conducted to date of patients with pemphigus and bullous pemphigoid report a similar efficacy for MMF to other immunosuppressants.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21924997     DOI: 10.1016/j.det.2011.06.012

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  4 in total

1.  Mycophenolic acid drug monitoring in patients with systemic sclerosis associated with diffuse skin and/or pulmonary involvement: A monocentric and retrospective French study.

Authors:  Paul Legendre; Benoit Blanchet; Raphael Porcher; Alice Bérezné; Marie Allard; Jonathan London; Benjamin Terrier; Pascal Cohen; Claire Le Jeunne; Luc Mouthon
Journal:  J Scleroderma Relat Disord       Date:  2020-08-06

Review 2.  Challenging Dermatologic Considerations Associated with Immune Checkpoint Inhibitors.

Authors:  Benjamin C Park; Seungyeon Jung; Steven T Chen; Anna K Dewan; Douglas B Johnson
Journal:  Am J Clin Dermatol       Date:  2022-06-16       Impact factor: 6.233

3.  Mycophenolate mofetil in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: a prospective pharmacokinetics and clinical study.

Authors:  B Chaigne; P Gatault; F Darrouzain; C Barbet; D Degenne; M François; P Szymanski; N Rabot; G Golea; E Diot; F Maillot; Y Lebranchu; H Nivet; G Paintaud; J-M Halimi; L Guillevin; M Büchler
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

Review 4.  A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management.

Authors:  Adriana T Lopez; Larisa Geskin
Journal:  Oncologist       Date:  2018-07-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.